Track topics on Twitter Track topics that are important to you
Indiana Blood And Marrow Transplantation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Indiana Blood And Marrow Transplantation articles that have been published worldwide.
We have published hundreds of Indiana Blood And Marrow Transplantation news stories on BioPortfolio along with dozens of Indiana Blood And Marrow Transplantation Clinical Trials and PubMed Articles about Indiana Blood And Marrow Transplantation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Indiana Blood And Marrow Transplantation Companies in our database. You can also find out about relevant Indiana Blood And Marrow Transplantation Drugs and Medications on this site too.
Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.
Zika virus has emerged as a potential threat to the Canadian blood supply system. Stem cell donors within Canadian Blood Services' Cord Blood Bank (CBB) and OneMatch Stem Cell and Marrow Network (OM) now undergo screening measures designed to reduce the risk of Zika virus transmission. The impact these screening measures have on cord blood and unrelated adult stem cell donations is currently unknown.
To evaluate the outcome of a salvage third autologous stem cell transplantation (ASCT) in relapsed multiple myeloma.
Although day 100 survival among allogeneic hematopoietic cell transplantation (HCT) recipients has improved over time, longer-term survival remains a challenge. The aim of this study was to identify prognostic factors for survival among patients surviving more than 100 days using baseline characteristics and factors identified within the first 100 days after transplantation. Of 413 patients undergoing a first allogeneic HCT from 2006 to 2014, 335 survived >100 days post-transplant. The majority underwent a ...
In this retrospective analysis using the Transplant Registry Unified Management Program, we identified 145 patients with human herpesvirus (HHV)-6 encephalitis among 6593 recipients. The cumulative incidences of HHV-6 encephalitis at 100 days after transplantation in all patients, recipients of bone marrow or PBSCs and recipients of cord blood were 2.3%, 1.6% and 5.0%, respectively. Risk factors identified in multivariate analysis were male sex, type of transplanted cells (relative risk in cord blood transp...
Informatics strategies and applications available to stem cell transplant (SCT) programs are diverse and changing rapidly. While most hospitals have electronic medical records (EMR), few are equipped with specialized SCT applications. Most EMR do not contain critical elements to support SCT practice and research. Strategies to optimize IT resources to support SCT programs are reviewed, and technical and workflow support are discussed. Guidance and rationale for the use of both SCT applications and EMR are e...
There is considerable heterogeneity in processing of stem cells for hematopoietic stem cell transplantation across Europe. The Foundation for the Accreditation of Cellular Therapy (FACT)-Joint Accreditation Committee International Society for Cellular Therapy and European Society for Blood and Marrow Transplantation (EBMT) (JACIE) standards provide minimum guidelines that, however, leave room for significant variations in practices at the individual transplantation center (TC).
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial, we investigated the efficacy of reduced intensity conditioning (RIC) before unrelated donor (URD) HSCT in children with TDT. Thirty-three children (1-17 years), received marrow or cord blood (UCB) allografts. Median time to neutrophil engraftment was 13 (range, 10-25) and 24 (range, 18-49) days; platelet engraftment was 23 (range, 12-46) and 50 (range, 31-234) days after marrow...
Idiopathic pneumonia syndrome (IPS) is a non-infectious pulmonary complication after hematopoietic cell transplantation (HCT) and is difficult to diagnose. We evaluated six candidate proteins in plasma samples at day 7 after HCT and at onset of IPS from 41 IPS cases to identify potential IPS diagnostic or prognostic biomarkers. Samples at similar times from 162 HCT recipients without documented infections and 37 HCT recipients with respiratory viral pneumonia served as controls. In multivariable models, a c...
As part of the 7th Annual francophone workshop series on the harmonization of clinical practices in allogeneic stem cell transplantation held in Lille in September 2016, our workgroup discussed how transplant centers might follow a collective approach to coding data. This was done mainly by analyzing the study results found in the literature that do not provide clear answers. In addition, we discuss practical ways of coding for both donor and recipient HLA typing in the European bone marrow transplantation ...
Chronic graft-versus-host disease (cGVHD) frequently affects the oral mucosa and is generally responsive to topical immunomodulatory therapies. Clinicians may benefit from guidance in choosing the most appropriate therapy with respect to practicality and cost.
The actual heparin concentration of harvested allogeneic bone marrow varies among harvest centers. We monitor the activated partial thromboplastin time (APTT) of the patient during bone marrow infusion and administer prophylactic protamine according to the APTT. We retrospectively reviewed the charts of consecutive patients who underwent bone marrow transplantation without bone marrow processing at our center between April 2007 and March 2016 (n=94). APTT was monitored during marrow transfusion in 52 patien...
We are reporting a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants (HAPLO), in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg, on days +3 and +5. The median age was 51 years (17-74), 51 patients (34%) had active disease at transplant, and the median follow up of surviving patients 903 days (150-1955). The cumulative incidence ...
The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) has been recently proposed to predict the probability of nonrelapse mortality (NRM) and overall survival (OS) in allogeneic hematopoietic stem cell transplantation (HSCT). However, the usefulness of HCT-CI in single-unit umbilical cord blood transplantation (UCBT) remains unclear. We investigated the impact of HCT-CI on the clinical outcomes of allogeneic HSCT in a single-center retrospective study including 53 recipients of UCBT (UC...
Chimerism analysis is an important step for the patient follow-up after hematopoietic stem cell transplantation. It is used to quantify the donor and the recipient part of a cell population issued from blood or bone marrow sample. In addition to hemogram, this technique is necessary to appreciate the quality of engraftment. The aim of this article is to propose some recommendation about methods, result analysis and therapeutic decision in hematopoietic stem cell transplantation for malignant or non-malignan...